EPHA3

Across TCGA pan-cancer cohorts, EPHA3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EPHA3 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EPHA3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EPHA3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where EPHA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.605	0.331	.023	4	view →
LUAD	DFS	Median	III,IV	0.367	1.000	.038	3	view →
LSCC	OS	Quartile	All	0.841	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EPHA3–PDAC (OS)

Open the PDAC breakdown →